Utilizing combination therapy in the treatment of Alzheimer's disease

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Alzheimer's disease may not yet be curable, but it is treatable. Two classes of drugs with differing mechanisms of action have received Food and Drug Administration approval for the treatment of Alzheimer's disease: the cholinesterase inhibitors and the N-methyl-D-aspartate receptor antagonist memantine (Ebixa®, Lundbeck; Namenda®, Forest Laboratories). Alzheimer's disease research directed at increasing the understanding of the underlying disease process has led to the identification of several other potential targets for drug development strategies. Due to the complexity of the disease, it is possible that combination therapy - concomitant use of agents with nonoverlapping or even synergistic mechanisms of action - may represent the best means available to enhance treatment effectiveness. This review evaluates the available data on combination therapy in Alzheimer's disease and provides an expert opinion on the use and implementation of combination therapy in clinical practice.

Original languageEnglish
Pages (from-to)799-808
Number of pages10
JournalExpert Review of Neurotherapeutics
Volume4
Issue number5
DOIs
StatePublished - Sep 2004

Fingerprint

Memantine
Alzheimer Disease
Drug Approval
Cholinesterase Inhibitors
Expert Testimony
United States Food and Drug Administration
Therapeutics
N-Methyl-D-Aspartate Receptors
Pharmaceutical Preparations
Research

Keywords

  • Alzheimer's disease
  • Combination therapy
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Utilizing combination therapy in the treatment of Alzheimer's disease. / Farlow, Martin.

In: Expert Review of Neurotherapeutics, Vol. 4, No. 5, 09.2004, p. 799-808.

Research output: Contribution to journalArticle

@article{77a6d60ba03349ec94dbddc8d1c4c63f,
title = "Utilizing combination therapy in the treatment of Alzheimer's disease",
abstract = "Alzheimer's disease may not yet be curable, but it is treatable. Two classes of drugs with differing mechanisms of action have received Food and Drug Administration approval for the treatment of Alzheimer's disease: the cholinesterase inhibitors and the N-methyl-D-aspartate receptor antagonist memantine (Ebixa{\circledR}, Lundbeck; Namenda{\circledR}, Forest Laboratories). Alzheimer's disease research directed at increasing the understanding of the underlying disease process has led to the identification of several other potential targets for drug development strategies. Due to the complexity of the disease, it is possible that combination therapy - concomitant use of agents with nonoverlapping or even synergistic mechanisms of action - may represent the best means available to enhance treatment effectiveness. This review evaluates the available data on combination therapy in Alzheimer's disease and provides an expert opinion on the use and implementation of combination therapy in clinical practice.",
keywords = "Alzheimer's disease, Combination therapy, Treatment",
author = "Martin Farlow",
year = "2004",
month = "9",
doi = "10.1586/14737175.4.5.799",
language = "English",
volume = "4",
pages = "799--808",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Utilizing combination therapy in the treatment of Alzheimer's disease

AU - Farlow, Martin

PY - 2004/9

Y1 - 2004/9

N2 - Alzheimer's disease may not yet be curable, but it is treatable. Two classes of drugs with differing mechanisms of action have received Food and Drug Administration approval for the treatment of Alzheimer's disease: the cholinesterase inhibitors and the N-methyl-D-aspartate receptor antagonist memantine (Ebixa®, Lundbeck; Namenda®, Forest Laboratories). Alzheimer's disease research directed at increasing the understanding of the underlying disease process has led to the identification of several other potential targets for drug development strategies. Due to the complexity of the disease, it is possible that combination therapy - concomitant use of agents with nonoverlapping or even synergistic mechanisms of action - may represent the best means available to enhance treatment effectiveness. This review evaluates the available data on combination therapy in Alzheimer's disease and provides an expert opinion on the use and implementation of combination therapy in clinical practice.

AB - Alzheimer's disease may not yet be curable, but it is treatable. Two classes of drugs with differing mechanisms of action have received Food and Drug Administration approval for the treatment of Alzheimer's disease: the cholinesterase inhibitors and the N-methyl-D-aspartate receptor antagonist memantine (Ebixa®, Lundbeck; Namenda®, Forest Laboratories). Alzheimer's disease research directed at increasing the understanding of the underlying disease process has led to the identification of several other potential targets for drug development strategies. Due to the complexity of the disease, it is possible that combination therapy - concomitant use of agents with nonoverlapping or even synergistic mechanisms of action - may represent the best means available to enhance treatment effectiveness. This review evaluates the available data on combination therapy in Alzheimer's disease and provides an expert opinion on the use and implementation of combination therapy in clinical practice.

KW - Alzheimer's disease

KW - Combination therapy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=4444382035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444382035&partnerID=8YFLogxK

U2 - 10.1586/14737175.4.5.799

DO - 10.1586/14737175.4.5.799

M3 - Article

C2 - 15853507

AN - SCOPUS:4444382035

VL - 4

SP - 799

EP - 808

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 5

ER -